Overview
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) designed as a stable analog of the ACTH 4-10 fragment. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia and Ukraine as a nasal spray for ischemic stroke, TIA, and cognitive impairment. It has been used clinically in Russia since 1991. Semax is notable for its BDNF (brain-derived neurotrophic factor) upregulation, which has attracted attention in neurotrophic factor research. It lacks the corticotropic effects of full ACTH while retaining the neuroprotective fragment, making it a targeted CNS research tool.
Mechanism
Semax's primary mechanisms involve upregulation of BDNF and its receptor TrkB in the hippocampus and prefrontal cortex, activation of the dopaminergic system in the striatum, and modulation of the enkephalin system. It also activates melanocortin receptors (MC4R) similarly to ACTH fragments but without adrenocortical stimulation. The BDNF upregulation is of particular research interest for neuroregeneration, learning, and memory consolidation studies.
Research Areas
Side Effects (Preclinical)
- – Generally well-tolerated in published literature
- – Mild nasal irritation (intranasal)
- – Rare: transient anxiety or agitation at higher doses
- – Mild stimulant effect
Cautions
- – For research use only outside Russia/Ukraine
- – Stimulant properties may interfere with sleep if administered late in the day
- – Limited independent Western replication of clinical claims
- – Acetylated variant (N-Ac Semax AMK) has different pharmacokinetics — confirm formulation in research design
Menopause & Women's Health Relevance
Cognitive changes — brain fog, word-finding difficulties, memory lapses — are reported by up to 60% of perimenopausal women. Estrogen is neuroprotective; its withdrawal accelerates the same pathways Semax targets via BDNF upregulation. The perimenopause window is now considered a critical period for brain health interventions, making BDNF-pathway compounds an active area of women's neuroscience research.
What the research shows
Semax’s stroke protection data comes from Russian clinical trials showing reduced neurological deficit and improved functional recovery in ischemic stroke patients. The BDNF upregulation finding (Dolotov et al., 2006) is the mechanistic basis for much of the nootropic interest, as BDNF is a critical mediator of synaptic plasticity, learning, and neuroprotection.
N-Acetyl Semax AMK is a metabolite form that some researchers prefer for enhanced CNS penetration and activity. Research protocols should specify which form is being used as they behave differently in vivo.
References
- Effects of the nootropic peptide Semax on brain BDNF — Dolotov OV et al. (2006)
- Clinical studies of Semax in ischemic stroke — Gusev EI et al. (1997)